Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model.

Storka A, Burian B, Führlinger G, Clive B, Sun T, Crevenna R, Gsur A, Mosgöller W, Wolzt M.

J Transl Med. 2013 May 7;11:117. doi: 10.1186/1479-5876-11-117.

2.

Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.

Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B.

J Immunol. 2001 Feb 15;166(4):2522-30.

3.

VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.

Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT, Nawata H.

Pancreas. 2005 Jan;30(1):62-70.

PMID:
15632701
4.

Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.

Burian B, Storka A, Marzluf BA, Yen YC, Lambers C, Robibaro B, Vonbank K, Mosgoeller W, Petkov V.

Peptides. 2010 Apr;31(4):603-8. doi: 10.1016/j.peptides.2009.12.014. Epub 2009 Dec 22.

PMID:
20026142
5.

Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.

Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG.

Int J Mol Med. 2002 Mar;9(3):233-43.

PMID:
11836629
6.
7.

Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.

Giunta S, Castorina A, Bucolo C, Magro G, Drago F, D'Agata V.

Peptides. 2012 Sep;37(1):32-9. doi: 10.1016/j.peptides.2012.06.004. Epub 2012 Jun 18.

PMID:
22721946
8.

Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.

Cunha-Reis D, Aidil-Carvalho Mde F, Ribeiro JA.

Hippocampus. 2014 Nov;24(11):1353-63. doi: 10.1002/hipo.22316. Epub 2014 Jul 7.

PMID:
24935659
9.

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA.

Cancer Res. 2000 Jun 1;60(11):3105-12.

10.

Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development.

Basille M, Cartier D, Vaudry D, Lihrmann I, Fournier A, Freger P, Gallo-Payet N, Vaudry H, Gonzalez B.

J Comp Neurol. 2006 Jun 1;496(4):468-78.

PMID:
16572459
11.

Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J.

Arthritis Rheum. 2008 Apr;58(4):1010-9. doi: 10.1002/art.23482.

12.

Contribution of vasoactive intestinal peptide to immune homeostasis in trophoblast-maternal leukocyte interaction under LPS stimulation.

Fraccaroli L, Grasso E, Hauk V, Cortelezzi M, Pérez Leirós C, Ramhorst R.

Neuroimmunomodulation. 2014;21(1):21-30. doi: 10.1159/000355039. Epub 2013 Oct 12.

PMID:
24135863
13.

Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.

Schulz S, Röcken C, Mawrin C, Weise W, Höllt V, Schulz S.

Clin Cancer Res. 2004 Dec 15;10(24):8235-42.

14.

Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.

García-Fernández MO, Collado B, Bodega G, Cortés J, Ruíz-Villaespesa A, Carmena MJ, Prieto JC.

Gynecol Endocrinol. 2005 Jun;20(6):327-33.

PMID:
16019382
15.

Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.

Sun W, Hong J, Zang YC, Liu X, Zhang JZ.

Int Immunol. 2006 Dec;18(12):1691-700. Epub 2006 Oct 31.

PMID:
17077178
16.

The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.

Dickinson T, Mitchell R, Robberecht P, Fleetwood-Walker SM.

Neuropharmacology. 1999 Jan;38(1):167-80.

PMID:
10193908
17.

Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.

Seoane IV, Ortiz AM, Piris L, Lamana A, Juarranz Y, García-Vicuña R, González-Álvaro I, Gomariz RP, Martínez C.

PLoS One. 2016 Feb 16;11(2):e0149141. doi: 10.1371/journal.pone.0149141. eCollection 2016.

18.

Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.

Nicol MR, Cobb VJ, Williams BC, Morley SD, Walker SW, Mason JI.

J Mol Endocrinol. 2004 Jun;32(3):869-77.

PMID:
15171718
19.

VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.

Yadav M, Huang MC, Goetzl EJ.

Cell Immunol. 2011;267(2):124-32. doi: 10.1016/j.cellimm.2011.01.001. Epub 2011 Jan 7.

PMID:
21295288
20.

Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.

Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC.

Cell Signal. 1999 Nov;11(11):813-9.

PMID:
10617284

Supplemental Content

Support Center